PATENT CLAIM ANALYSIS

Application Number: 16032002
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "269000"]

Abstract:
Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile. Also described are pharmaceutical compositions suitable for administration to a mammal that include the lysine specific demethylase-1 inhibitor, and methods of using the lysine specific demethylase-1 inhibitor for treating diseases or conditions that are associated with lysine specific demethylase-1 activity.

Claim (Index 6):
The crystalline form of  claim 4 , wherein the crystalline form exhibits a characteristic XRPD pattern with characteristic peaks at 4.9\u00b0 2-Theta, 9.7\u00b0 2-Theta, 13.4\u00b0 2-Theta, 18.0\u00b0 2-Theta, and 18.5\u00b0 2-Theta.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 95.0
- Lexical Diversity: 1.46
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15793512', '15344426', '15262522', '15975449', '14406520']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7963667443875827
- 35 USC 102 Novelty (BERT): 0.5945814417957632
- Combined Prediction Score: 0.7761882141284008
- Mean Citation Score: 354.167534
- Max Citation Score: 480.5556
- Similarity Product: 479.254476015544

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test